SUN Pharmaceutical Industries Limited Bambuterol Export Data — India (DGFT 2022–2026)

Name: SUN Pharmaceutical Industries Limited Bambuterol Export Records India — #1 Exporter, 8 Shipments, $72.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Bambuterol

India Pharmaceutical Trade Intelligence

$141.2K4 Suppliers2 CountriesHS 30049099

ExportsIndia → MYANMAR95.3%India → AFGHANISTAN4.7%

#1 Supplier: SUN PHARMACEUTICAL #1 Buyer: MYIT MAHAR

SUN Pharmaceutical Industries Limited — Bambuterol Exporter #1 | $72.6K Trade Value | TransData Nexus | TransData Nexus

SUN Pharmaceutical Industries Limited — Bambuterol Exporter Profile

Indian Pharmaceutical Exporter · #1 for Bambuterol · $72.6K export value · DGFT Verified

SUN Pharmaceutical Industries Limited is the #1 Indian exporter of Bambuterol with $72.6K in export value and 8 verified shipments. SUN Pharmaceutical Industries Limited holds a 51.4% market share in Bambuterol exports across 1 countries. The company exports 118 pharmaceutical products worth $979.8M across 25 therapeutic categories.

SUN Pharmaceutical Industries Limited — Bambuterol Export Profile: Buyers & Destinations

SUN Pharmaceutical Industries Limited Bambuterol export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Bambuterol?

Country	Value	Shipments	Share
MYANMAR	$134.6K	10	95.3%
AFGHANISTAN	$6.7K	2	4.7%

India exports Bambuterol to 2 countries. The top destination is MYANMAR (95.3%).

Who Are the Top Buyers of Bambuterol from India?

Buyer	Country

Which Indian Ports Ship Bambuterol Exports?

Port	Shipments	% Share
NHAVA SHEVA SEA (INNSA1)	4	33.3%
Delhi Air	2	16.7%
DHANNAD ICD (INDHA6)	1	8.3%
GRFL SAHNEWAL LUDHIANA ICD (INSGF6)	1	8.3%
Dadriacpl Cfs	1	8.3%
INDORE AIR	1	8.3%
GOPALPUR PORT	1	8.3%
DELHI AIR	1	8.3%

Geopolitical & Trade Policy Impact on SUN Pharmaceutical Industries Limited's Bambuterol Exports

Sun Pharma's export operations, valued at $979.8 million, are significantly influenced by current geopolitical events. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to Europe and North Africa. Major shipping lines have imposed 'Emergency Risk Surcharges,' increasing freight costs and extending transit times by 10–15 days. These delays pose risks to the integrity of time-sensitive and temperature-controlled pharmaceutical shipments. (pharmaceuticalcommerce.com)

In the United States, policy shifts towards domestic manufacturing and the imposition of tariffs on imported pharmaceuticals have created challenges for Indian exporters. Sun Pharma, which supplies a substantial portion of generics to the U.S. market, faces potential reductions in export volumes due to these protectionist measures. The company is exploring strategies such as establishing local partnerships and investing in U.S.-based manufacturing to mitigate these impacts. (odrindia.in)

The European Union's implementation of the Carbon Border Adjustment Mechanism (CBAM) introduces additional compliance requirements for exporters. Sun Pharma must adapt to these regulations to maintain its market presence in the EU, necessitating investments in sustainable manufacturing practices and comprehensive reporting mechanisms. (sgeexport.com)

SUN Pharmaceutical Industries Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards remains a critical focus for Sun Pharma. The company has encountered challenges with the U.S. FDA, including import alerts and non-compliance letters for certain facilities. Addressing these issues involves implementing corrective actions and awaiting reinspection to resume full operations. (business-standard.com)

Globally, the pharmaceutical industry faces increasing scrutiny regarding quality standards. Sun Pharma's commitment to adhering to Good Manufacturing Practices (GMP) and other regulatory requirements is essential to maintain its export licenses and market reputation. Continuous investment in quality control systems and compliance infrastructure is imperative to navigate the evolving regulatory landscape.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Bambuterol shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: SUN Pharmaceutical Industries Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 2+ countries, 7+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

MYIT MAHAR TRADING CO LTD	MYANMAR	$62.0K	2
MYIT MAHAR TRADING CO., LTD.	MYANMAR	$37.8K	5

Bambuterol

Bambuterol

SUN Pharmaceutical Industries Limited — Bambuterol Exporter Profile

SUN Pharmaceutical Industries Limited — Bambuterol Export Profile: Buyers & Destinations

Where Does India Export Bambuterol?

Who Are the Top Buyers of Bambuterol from India?

What Is India's Total Bambuterol Export Value and How Much Does SUN Pharmaceutical Industries Limited Contribute?

What Is the Average Shipment Value for SUN Pharmaceutical Industries Limited's Bambuterol Exports?

How Does SUN Pharmaceutical Industries Limited Compare to Other Indian Bambuterol Exporters?

Which Indian Ports Ship Bambuterol Exports?

Geopolitical & Trade Policy Impact on SUN Pharmaceutical Industries Limited's Bambuterol Exports

SUN Pharmaceutical Industries Limited — Regulatory Compliance & Quality Standards

About SUN Pharmaceutical Industries Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Bambuterol Export Data from SUN Pharmaceutical Industries Limited

Bambuterol Stats

Company Overview

Top Products by SUN Pharmaceutical Industries Limited

Related Analysis

Need Detailed Export Data?

Data Source